|
|
|
|
|
BERLIN, Germany, Sept 25, 2018 - (ACN Newswire) - Myelo Therapeutics GmbH announced today that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to its orally applied new chemical entity Myelo001 for the treatment of Acute Radiation Syndrome (ARS).
ARS, also known as radiation toxicity or radiation sickness, is an acute illness that presents after exposure to high levels of radiation, caused by a nuclear accident or attack. It can lead to severe health consequences, including death. The US government is encouraging the development of new drugs to prevent or treat ARS.
Myelo001 is a new, clinical-stage adjuvant cancer therapy for the treatment of chemotherapy- and radiotherapy-induced myelosuppression. Preclinical and clinical studies have shown that Myelo001 applied orally is effective in reducing hematopoietic symptoms caused by chemotherapy and radiation. Comprehensive chronic toxicology and safety studies, as well as clinical studies, have confirmed an excellent safety profile of Myelo001.
The US FDA Orphan Drug Designation program provides incentives to companies that are developing therapies for diseases which affect fewer than 200,000 people in the US. The benefits of achieving Orphan Drug Designation include close guidance by the FDA, which may accelerate the path to potential marketing approval, orphan drug research grants, tax credits, waivers of regulatory fees, as well as a 7-year market exclusivity upon marketing approval.
Therapies for ARS qualify as medical countermeasures (MCMs), which are FDA-regulated products that may be used in the event of a potential public health emergency caused by a biological, chemical, or radiological/nuclear material. When developing MCMs for radiological and nuclear threats, it is not ethical or feasible to test a drug's efficacy by exposing human subjects to high levels of radiation. Given this, the FDA may grant approval based on well-controlled non-clinical studies. There is also a requirement to demonstrate the drug's safety in humans.
MCMs are purchased and stockpiled by the Department of Health and Human Services, the Department of Defense, and various foreign governments and militaries.
The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.
Upon approval, the FDA may award a priority review voucher (PRV) to sponsors of MCMs. A PRV allows for an expedited review process for a new drug application. A sponsor may also sell awarded PRVs to other drug companies. Past transactions of PRVs have resulted in market prices of up to USD 350 million.
About Myelo Therapeutics
Myelo Therapeutics is a pharmaceutical company based in Berlin and Dresden, Germany, that is developing innovative treatments in areas of high unmet medical needs, such as Chemotherapy-induced Myelosuppression (CIM), Radiation-induced Myelosuppression (RIM), and Acute Radiation Syndrome (ARS). For more information, visit www.myelotherapeutics.com.
Contact: Myelo Therapeutics GmbH, Till Erdmann, Kastanienallee 56, 10119 Berlin, Germany. Phone: +49 (0) 170 9126 402, info@myelotherapeutics.com
The information included in this press release concerns a drug use that has not been approved by the Food and Drug Administration.
###
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Myelo Therapeutics GmbH via Globenewswire
Topic: Press release summary
Source: Myelo Therapeutics GmbH
Sectors: Science & Research, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
Latest Press Releases
Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence
May 15, 2026 22:20 HKT/SGT
|
|
|
NEC completes construction of approximately 2,250 km EMCS submarine cable linking Pacific island nations
Friday, May 15, 2026 4:36:00 PM
|
|
|
Fujitsu and Science Tokyo launch joint research hub for quantum hardware advancement and talent development
Friday, May 15, 2026 4:12:00 PM
|
|
|
Fujitsu and IBM Japan formalize collaboration in healthcare sector
Friday, May 15, 2026 3:42:00 PM
|
|
|
Toyota Launches All-New Land Cruiser "FJ" Series in Japan
Friday, May 15, 2026 2:24:00 PM
|
|
|
Mitsubishi Motors Signs Memorandum of Understanding with FPT Japan Holdings to Study Collaboration in Software and Digital Domain
Friday, May 15, 2026 2:10:00 PM
|
|
|
Your Go-To Travel Checklist for Smarter, Reward-Focused Travel Planning
May 15, 2026 14:00 HKT/SGT
|
|
|
NEC Launches Orbital Transfer Vehicle Development Project Aiming for Asia's First Vehicle Deployment through JAXA's Space Strategy Fund Program
Friday, May 15, 2026 1:55:00 PM
|
|
|
Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program
May 15, 2026 07:00 HKT/SGT
|
|
|
JCB and Discover(R) Network Mark 20 Years of Collaboration 
Thursday, May 14, 2026 10:00:00 PM
|
|
|
|
|
More Press release >> |
|
|
|
